Michael Gelband’s 4D Molecular Therapeutics FDMT Stock Holding History

Michael Gelband’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,529	Closed	-$145K	–	1716
2026 Q1	$145K	Sell	15,529 -23,646	-60%	-$206K	﹤0.01%	1413
2025 Q4	$294K	Buy	+39,175	New	+$397K	﹤0.01%	1316
2024 Q3	–	Sell	-49,945	Closed	-$1.05M	–	1759
2024 Q2	$1.05M	Buy	+49,945	New	+$1.25M	0.01%	1011
2023 Q4	–	Sell	-29,307	Closed	-$373K	–	1650
2023 Q3	$373K	Buy	+29,307	New	+$490K	﹤0.01%	1340
2021 Q1	–	Sell	-33,152	Closed	-$1.37M	–	2250
2020 Q4	$1.37M	Buy	+33,152	New	+$1.37M	0.01%	700

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Michael Gelband's FDMT Position: Q2 2026 in Review

Michael Gelband sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 15,529 shares — an estimated $145K sold.

Michael Gelband first reported a position in FDMT in Q4 2020 and held it in 5 quarters. The position peaked at $1.37M in Q4 2020. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Michael Gelband reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 15,529 4D Molecular Therapeutics shares in Q2 2026, an estimated $145K.
Michael Gelband first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 5 quarters.
Michael Gelband's 4D Molecular Therapeutics position peaked at $1.37M in Q4 2020.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.